Characteristics of repeatedly secluded elderly female schizophrenic inpatients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 5, 2003, Pages 771-774

  Nakajima, Mami ^a   Terao, Takeshi ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Antipsychotics; Dopamine; Female; Prolactin; Schizophrenia

Indexed keywords

BROMPERIDOL; CHLORPROMAZINE; CLOSPIPRAMINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PROLACTIN; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZOTEPINE;

ADULT; AGE DISTRIBUTION; AGED; AGING; ANAMNESIS; ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE ACTION; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MENTAL HOSPITAL; PREDICTION; PROLACTIN BLOOD LEVEL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SYMPTOM;

EID: 0042131953     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00107-6     Document Type: Article

References (35)

1. Appleberg B., Katila H., Rimon R. Inverse correlation between hallucinations and serum prolactin in patients with non-affective psychoses. Schizophr. Res. 44:2000;183-186.
2. Convertino K., Pinto R.P., Fiester A.R. Use of inpatient seclusion at a community mental health center. Hosp. Community Psychiatry. 31:1980;848-850.
3. Dhossche D.M., Ghani S.O. A study on recidivism in the psychiatric emergency room. Ann. Clin. Psychiatry. 10:1998;59-67.
4. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1995;Igaku-Shoin, Tokyo, Japan. First Japanese edition.
5. Ferrier I.N., Johnstone E.C., Crow T.J. Hormonal effects of apomorphine in schizophrenia. Br. J. Psychiatry. 144:1984;349-357.
6. Fisher W.A. Restraint and seclusion: a review of the literature. Am. J. Psychiatry. 151:1994;1584-1591.
7. Friedman S., Margolis R., David O.J., Kesselman M. Predicting psychiatric admission from an emergency room: psychiatric, psychosocial, and methodological factors. J. Nerv. Ment. Dis. 171:1983;155-158.
8. Gerlock A., Solomons H.C. Factors associated with the seclusion of psychiatric patients. Perspect. Psychiatr. Care. 21:1983;46-53.
9. Green A.I., Brown W.A. Prolactin and neuroleptic drugs. Endocrinol. Metab. Clin. N. Am. 17:1988;213-223.
10. Gutheil T.G. Observation on the theoretical bases for seclusion of the psychiatric inpatient. Am. J. Psychiatry. 135:1978;325-328.
11. Hammil K., McEvoy J.P., Koral H., Schneider N. Hospitalized schizophrenic patient views about seclusion. J. Clin. Psychiatry. 50:1989;174-177.
12. Johnstone E.C., Crow T.J., Mashiter K. Anterior pituitary hormone secretion in chronic schizophrenia: an approach to neurohumoral mechanisms. Psychol. Med. 7:1977;223-228.
13. 2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry. 158:2001;360-369.
14. Kellner R., Buckman M.T., Fava G.A., Pathak D. Hyperprolactinemia, distress, and hostility. Am. J. Psychiatry. 141:1984;759-763.
15. Kleinman J.E., Weinberger D.R., Rogol A.D., Bigelow L.B., Klein S.T., Gillin J.C., Wyatt R.J. Plasm prolactin concentrations and psychopathology in chronic schizophrenia. Arch. Gen. Psychiatry. 39:1982;655-657.
16. Kulkarni J.K., Keks N.A., Stuart G., Mackie B., Minas I.H., Singh B.S., Copolov D.L. Relationship of psychotic symptoms to haloperidol-stimulated prolactin release. Acta Psychiatr. Scand. 82:1990;271-274.
17. Kuruvilla A., Peedicayil J., Srikrishna G., Kuruvilla K., Kanagasabapathy A.S. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin. Exp. Pharmacol. Physiol. 19:1992;603-606.
18. Kuruvilla A., Srikrishna G., Peedicail J., Kuruvilla K., Kanagasabapathy A.S. A study on serum prolactin levels in schizophrenia: correlation with positive and negative symptoms. Int. Clin. Psychopharmacol. 8:1993;177-179.
19. Magharious W., Goff D.C., Amico E. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Res. 77:1998;159-166.
20. Mattson M.R., Sacks M.H. Seclusion: uses and complications. Am. J. Psychiatry. 135:1978;1210-1213.
21. Meltzer H.Y., Busch D. Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis. Psychiatry Res. 9:1983;285-299.
22. Oldham J.M., Russakoff L.M., Prusnofsky L. Seclusion: patterns and milieu. J. Nerv. Ment. Dis. 171:1983;645-650.
23. Plutchik R., Karasu T.B., Conte H.R., Siegel B., Jerrett I. Toward a rationale for the seclusion process. J. Nerv. Ment. Dis. 166:1978;571-579.
24. Ramchandani D., Akhtar S., Helfrich J. Seclusion of psychiatric inpatients: a general hospital perspective. Int. J. Soc. Psychiatry. 27:1981;309-315.
25. Reavley A., Fisher A.D., Owen D., Creed F.H., Davis J.R. Psychological distress in patients with hyperprolactinemia. Clin. Endocrinol. (Oxf.). 47:1997;343-348.
26. Rinieris P., Hatzimanolis J., Markianos M., Stefanis C. Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients. Neuropsychobiology. 22:1989;146-149.
27. Roncoroni D. Relations between psychotic symptoms and serum prolactin levels. Pharmacopsychiatry. 22:1989;71-75.
28. Schwab P.J., Lahmeyer C.B. The uses of seclusion on a general hospital psychiatric unit. J. Clin. Psychiatry. 40:1979;228-231.
29. Seeman P., Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am. J. Psychiatry. 156:1999;876-884.
30. Smith S., Wheeler M.J., Murray R., O'keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J. Clin. Psychopharmacol. 22:2002;109-114.
31. Soloff P.H. Behavioral precipitants of restraint in the modern milieu. Compr. Psychiatry. 19:1978;179-184.
32. Soloff P.H., Turner S.M. Patterns of psychiatric inpatients to patterns of seclusion: a prospective study. J. Nerv. Ment. Dis. 169:1981;37-44.
33. Thompson P. The use of seclusion in psychiatric hospitals in the Newcastle area. Br. J. Psychiatry. 149:1986;471-474.
34. Von Bahr C., Wiesel F.A., Movin G., Eneroth P., Jansson P., Nilsson L., Ogenstad S. Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers. Psychopharmacology (Berl.). 103:1991;443-448.
35. Yessavage J.A. Correlates of dangerous behavior by schizophrenics in hospital. J. Psychiatr. Res. 18:1984;225-231.